Imatinib with Eliglustat Interaction Details
Brand Names Associated with Imatinib
- Gleevec®
- Imatinib
Brand Names Associated with Eliglustat
- Cerdelga®
- Eliglustat
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Nov 07, 2023
Interaction Effect
Increased eliglustat exposure and subsequent prolongation of the QT interval
Interaction Summary
Concomitant use with fluconazole (a moderate CYP3A inhibitor) increased eliglustat AUC 2.5 to 3.2-fold, while concomitant use with fluconazole plus terbinafine (a strong CYP2D6 inhibitor) increased eliglustat AUC 5-fold to 13.6-fold. In extensive CYP2D6 metabolizers, reduce the eliglustat dose to 84 mg once daily if used concomitantly with a moderate CYP3A inhibitor. In intermediate or poor CYP2D6 metabolizers, avoid concomitant use of a moderate CYP3A inhibitor. In extensive and intermediate CYP2D6 metabolizers, eliglustat use is contraindicated with the concomitant use of both a moderate CYP3A inhibitor and strong or moderate CYP2D6 inhibitor.
Severity
Contraindicated
Onset
Unspecified
Evidence
Theoretical
How To Manage Interaction
In extensive CYP2D6 metabolizers, reduce the eliglustat dose to 84 mg once daily if used concomitantly with a moderate CYP3A inhibitor. In intermediate or poor CYP2D6 metabolizers, avoid concomitant use of a moderate CYP3A inhibitor. In extensive and intermediate CYP2D6 metabolizers, eliglustat use is contraindicated with the concomitant use of both a moderate CYP3A inhibitor and strong or moderate CYP2D6 inhibitor.
Mechanism Of Interaction
Inhibition of CYP3A4-mediated eliglustat metabolism
Literature Reports
A) In patients with Gaucher disease type 1, eliglustat use with the moderate CYP3A4 inhibitor, fluconazole, was predicted to cause a 2.8-fold increase in eliglustat Cmax and a 3.2-fold increase in AUC in extensive CYP2D6 metabolizers and 2.5- and 2.9-fold increases, respectively, in intermediate CYP2D6 metabolizers. In poor metabolizers taking eliglustat 84 mg/day, concomitant use of fluconazole was predicted to increase Cmax by 2.4-fold and AUC by 3-fold
B) Among extensive CYP2D6 metabolizers with Gaucher disease type 1, simulations suggested that eliglustat Cmax would increase 10.2-fold and AUC would increase 13.6-fold with concomitant use of fluconazole (a moderate CYP3A inhibitor) plus terbinafine (a strong CYP2D6 inhibitor). Among intermediate CYP2D6 metabolizers, the predicted eliglustat Cmax and AUC was 4.2- and 5-fold higher, respectively, with concurrent use of fluconazole plus terbinafine .
Imatinib Overview
-
Imatinib is used to treat certain types of leukemia (cancer that begins in the white blood cells) and other cancers and disorders of the blood cells. Imatinib is also used to treat certain types of gastrointestinal stromal tumors (GIST; a type of tumor that grows in the walls of the digestive passages and may spread to other parts of the body). Imatinib is also used to treat dermatofibrosarcoma protuberans (a tumor that forms under the top layer of skin) when the tumor cannot be removed surgically, has spread to other parts of the body, or has come back after surgery. Imatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Eliglustat Overview
-
Eliglustat is used to treat Gaucher disease type 1 (a condition in which a certain fatty substance is not broken down normally in the body and builds up in some organs and causes liver, spleen, bone, and blood problems) in certain people. Eliglustat is in a class of medications called enzyme inhibitors. It works by preventing the body from producing the fatty substance so that less of it will build up in the body and cause symptoms.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.